Hopp til hovedinnhold

Systemisk sklerose

Sist revidert:
Sist revidert av:

Definisjon:
Er en multiorgan sykdom karakterisert ved avleiring og akkumulering av store mengder kollagen og ekstracellulær-matrix-molekyler.
Forekomst:
Sjelden sykdom.
Symptomer:
Symmetrisk sklerose i huden og skader på spiserør, lunger, hjerte og nyrer m.m.
Funn:
Særlig hudforandringer, men etter som sykdommen brer om seg gjøres funn også fra andre organer.
Diagnostikk:
Blodprøver viser økt SR, trombocytopeni, hypergammaglobulinemi, ev. økt kreatinin, ANA-positiv, histologiske forandringer i hudbiopsier, bildediagnostikk kan vise ev. andre organskader.
Behandling:
Avhenger av symptomene og deres kompleksitet. En lang rekke medikamenter kan prøves, men ingen har helbredende effekt.
  1. Kowal-Bielecka O, Fransen J, Avouac J EUSTAR Coauthors, et alUpdate of EULAR recommendations for the treatment of systemic sclerosisAnnals of the Rheumatic Diseases 2017;76:1327-1339. ard.bmj.com  
  2. Schwartz RA. Systemic sclerosis. Medscape, last updated Mar 13, 2018. emedicine.medscape.com  
  3. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 09, 2015. UpToDate  
  4. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223-35. pmid:17692364 PubMed  
  5. Gran JT, Molberg Ø, Midtvedt Ø. Patofysiologiske aspekter ved systemisk sklerose. Tidsskr Nor Lægeforen 2005; 125: 2622-3. PubMed  
  6. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10. PubMed  
  7. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 06, 2017. UpToDate  
  8. Varga J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 05, 2017. UpToDate  
  9. Gran JT, Midtvedt Ø. Iskemiske sår ved systemisk bindevevssykdom. Tidsskr Nor Lægeforen 2006; 126: 3089-92. PubMed  
  10. Kuwana M. Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. J Nippon Med Sch 2017; 84(2): 56-63. pmid:28502960 PubMed  
  11. Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken). 2012; 64(9):1405-14. PubMed  
  12. Derrett-Smith EC, Nihtyanova SI, Harvey J, et al. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) 2013; 52:1824. PubMed  
  13. Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Oct 10, 2014. UpToDate  
  14. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-91. PubMed  
  15. García de la Peña Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Román Ivorra JA, et al. Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015; 35(9):1447-59. PubMed  
  16. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66. New England Journal of Medicine  
  17. Martinez FJ, McCune J. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006; 354: 2707-9. PubMed  
  18. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015 Jun; 74:1188. Doi: 10.1136/annrheumdis-2013-204522 DOI  
  19. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet respir Med 2016; 4: 708. doi:27469583
  20. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 PMID: 31112379 PubMed  
  21. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490-8. PubMed  
  22. Sullivan KM., Goldmuntz EA., Keyes-Elstein L. et al.. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378: 35-47. pmid:29298160 PubMed  
  23. Onishi A, Sugiyama D, Kumagai S, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013 Jul;65(7):1913-21. doi: 10.1002/art.37969. DOI  
  24. Tennøe AH, Murbræch K, Andreassen JC, et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. Journal of the American College of Cardiology, volume 72, issue 15, October 2018.
  25. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim
  • Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim

Tidligere fagmedarbeidere

  • Sylvi Torvund, spesialist i allmennmedisin, Nidarvold legesenter, Trondheim
  • Mette Mogensen, overlæge, klinisk lektor, ph.d., Dermato-Venerologisk afd. D, Bispebjerg og Frederiksberg Hospital